Genprex 10-K Reveals $0 Revenue, $16.2M Net Loss; Halts Key Oncology Trial
Summary
Genprex filed its annual 10-K report, disclosing zero product revenue and a net loss of $16.2 million for the year ended December 31, 2025, an improvement from the prior year's $21.1 million loss. Critically, the company also announced the halting of enrollment for its Acclaim-2 oncology trial due to slow recruitment, reallocating resources to Acclaim-1 and Acclaim-3. For a micro-cap, pre-revenue biotech, the continued significant cash burn and the setback of a clinical trial halt are material concerns for its financial runway and pipeline progress. Investors will be closely watching the interim analyses for Acclaim-1 and Acclaim-3 expected in the second half of 2026, as well as the advancement of its diabetes program and overall cash management.
At the time of this announcement, GNPX was trading at $1.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $1.71 to $55.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.